These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3115884)

  • 1. VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies.
    Anderson H; Scarffe JH; Lambert M; Smith DB; Chan CC; Chadwick G; McMahon A; Chang J; Crowther D; Swindell R
    Hematol Oncol; 1987; 5(3):213-22. PubMed ID: 3115884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The efficacy of VAD chemotherapy for refractory lymphoid malignancies].
    Gotoh H; Oku N; Inaba T; Murakami S; Oku N; Takeda N; Itoh K; Fujita N; Ura Y; Nakanishi S
    Rinsho Ketsueki; 1991 Aug; 32(8):822-30. PubMed ID: 1942521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of refractory multiple myeloma with vincristine, adriamycin, and dexamethasone].
    Ma MX; Yiu JR; Wu SL
    Zhonghua Nei Ke Za Zhi; 1989 May; 28(5):267-9, 313. PubMed ID: 2805963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
    Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VAD chemotherapy as remission induction for multiple myeloma.
    Anderson H; Scarffe JH; Ranson M; Young R; Wieringa GS; Morgenstern GR; Fitzsimmons L; Ryder D
    Br J Cancer; 1995 Feb; 71(2):326-30. PubMed ID: 7841049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.
    Gertz MA; Kalish LA; Kyle RA; Hahn RG; Tormey DC; Oken MM
    Am J Clin Oncol; 1995 Dec; 18(6):475-80. PubMed ID: 8526187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
    Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
    J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma.
    Cook G; Sharp RA; Tansey P; Franklin IM
    Br J Haematol; 1996 Jun; 93(4):931-4. PubMed ID: 8703828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential value of vintristine-adriamycin-dexamethasone combination chemotherapy (VAD) in refractory and rapidly progressive myeloma.
    Collin R; Greaves M; Preston FE
    Eur J Haematol; 1987 Sep; 39(3):203-8. PubMed ID: 3678471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen.
    Stenzinger W; Blömker A; Hiddemann W; van de Loo J
    Blut; 1990; 61(2-3):55-9. PubMed ID: 2207342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VAD chemotherapy for refractory multiple myeloma.
    Lokhorst HM; Meuwissen OJ; Bast EJ; Dekker AW
    Br J Haematol; 1989 Jan; 71(1):25-30. PubMed ID: 2644970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contribution of anthracyclines in treatment of lymphoproliferative disorders].
    Coiffier B
    Pathol Biol (Paris); 1987 Jan; 35(1):75-8. PubMed ID: 2436132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
    Phillips JK; Sherlaw-Johnson C; Pearce R; Davies JM; Reilly JT; Newland AC; Cawley JC
    Leuk Lymphoma; 1995 May; 17(5-6):465-72. PubMed ID: 7549839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and toxicity of VAD in the treatment of myeloma and related disorders.
    Sheehan T; Judge M; Parker AC
    Scand J Haematol; 1986 Nov; 37(5):425-8. PubMed ID: 3810040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma.
    Fosså A; Muer M; Kasper C; Welt A; Seeber S; Nowrousian MR
    Leukemia; 1998 Mar; 12(3):422-6. PubMed ID: 9529138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
    Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.